Human Anti-DLL4 Recombinant Antibody (HPAB-0156CQ)

Customer Review

There are currently no Customer reviews or questions for HPAB-0156CQ. Click the button above to contact us or submit your feedback about this product.

Citations

1. Park, Mi Ae, et al. "Activation of the arterial program drives development of definitive hemogenic endothelium with lymphoid potential." Cell reports 23.8 (2018): 2467-2481. https://doi.org/10.1016/j.celrep.2018.04.092
   This research investigates how activating the arterial program drives the development of definitive hemogenic endothelium with lymphoid potential from human pluripotent stem cells (hPSCs). The study demonstrates that enhancing arterial specification through ETS1 overexpression or modulation of MAPK/ERK signaling pathways at the mesodermal stage of development dramatically improves the formation of arterial-type hemogenic endothelium (AHE) with a specific phenotype (CD144+CD43-CD73-DLL4+CXCR4+/-). Blood cells generated from this arterial hemogenic endothelium showed more than 100-fold enrichment in T cell precursor frequency and possessed the capacity to produce B lymphocytes and red blood cells expressing high levels of BCL11a and β-globin, indicating definitive hematopoiesis with lymphoid potential.
   Creative Biolabs provided DLL4 neutralizing antibodies that were instrumental in confirming that the effect of ETS1 upregulation on hematopoiesis is mediated through NOTCH signaling. When these antibodies were used to block DLL4, they effectively abrogated the enhancing effect of ETS1 on blood production and colony-forming cell potential, demonstrating that DLL4 expression and NOTCH activation are essential for ETS1-mediated promotion of the definitive hematoendothelial program. This contribution helped establish the molecular pathway linking arterial specification to lymphoid potential in hPSC-derived hematopoietic cells.

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Publications

Our products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of publications that cite this product.

Park, Mi Ae, et al. "Activation of the arterial program drives development of definitive hemogenic endothelium with lymphoid potential." Cell reports 23.8 (2018): 2467-2481.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "DLL4"

Select a product category from the dropdown menu below to view related products.